Paul R Tarnasky
Overview
Explore the profile of Paul R Tarnasky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
496
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barrera Gutierrez J, Greenburg I, Shah J, Acharya P, Cui M, Vivian E, et al.
Cureus
. 2023 Nov;
15(10):e46809.
PMID: 37954725
Background Severe acute pancreatitis (SAP) has a mortality rate as high as 40%. Early identification of SAP is required to appropriately triage and direct initial therapies. The purpose of this...
2.
Hirapara B, Witheiler D, Tarnasky P, Villamil M
Cureus
. 2023 Mar;
15(2):e35453.
PMID: 36994252
Esophageal involvement of lichen planus is an under-reported and under-diagnosed manifestation that should prompt immediate treatment given its high rate of complications. We highlight a rare case of a 62-year-old...
3.
4.
Tyberg A, Raijman I, Gaidhane M, Trindade A, Shahid H, Sarkar A, et al.
Endosc Int Open
. 2022 Aug;
10(8):E1065-E1072.
PMID: 35979031
Optical coherence tomography (OCT) is a new technology available for evaluation of indeterminate biliary strictures. It allows under-the-surface visualization and preliminary studies have confirmed standardized characteristics associated with malignancy. The...
5.
John E, Tarnasky P, Kedia P
Transl Gastroenterol Hepatol
. 2021 Nov;
6:63.
PMID: 34805585
Cholangiocarcinoma, a malignancy of the epithelial cells in the intrahepatic or extrahepatic biliary tree, is often diagnosed at later stages. Median survival duration ranges from 3 to 9 months with...
6.
Tarnasky P
Gastroenterol Hepatol (N Y)
. 2021 May;
16(5):262-264.
PMID: 34035730
No abstract available.
7.
Han S, Kahaleh M, Sharaiha R, Tarnasky P, Kedia P, Slivka A, et al.
Gastrointest Endosc
. 2021 Apr;
94(3):569-576.e1.
PMID: 33798541
Background And Aims: Patients with primary sclerosing cholangitis (PSC) and dominant biliary strictures carry increased risk for the development of cholangiocarcinoma. Although ERCP-based techniques including brush cytology and intraductal biopsy...
8.
Tarnasky P, Lee D, Kedia P
VideoGIE
. 2020 Dec;
5(12):697-698.
PMID: 33319147
No abstract available.
9.
Tyberg A, Mishra A, Cheung M, Kedia P, Gaidhane M, Craig C, et al.
Endosc Ultrasound
. 2020 Jul;
9(6):392-396.
PMID: 32687074
Background And Objective: EUS-guided-biliary drainage (EUS-BD) is an efficacious and safe option for patients who fail ERCP. EUS-BD is a technically challenging procedure. The aim of this study was to...
10.
Tyberg A, Bodiwala V, Kedia P, Tarnasky P, Khan M, Novikov A, et al.
Endosc Ultrasound
. 2020 Jun;
9(3):175-179.
PMID: 32584312
Background And Objective: EUS-guided pancreatic drainage (EUS-PD) is an efficacious, acceptable risk option for patients with pancreatic duct obstruction who fail conventional ERCP. The aim of this study was to...